来迪派韦-索磷布韦联合利巴韦林治疗初治基因3型丙型肝炎病毒感染:一项开放标签研究
这项在加拿大15个中心开展的开放标签试验纳入111例初治基因3型HCV感染患者,其中35%有代偿期肝硬化,均接受来迪派韦-索磷布韦联合基于体重的利巴韦林治疗12周。总体SVR12为89%(95%CI 82%-94%),无肝硬化患者为94%,肝硬化患者为79%。治疗失败者未出现治疗 emergent 耐药突变。
要点
- 初治基因3型HCV无肝硬化患者接受12周来迪派韦-索磷布韦联合利巴韦林治疗SVR12达94%。
- 代偿期肝硬化患者SVR12为79%,低于无肝硬化患者。
- 治疗失败者未检测到治疗 emergent 耐药突变。
核心结论
- 在初治基因3型HCV感染者中,12周来迪派韦-索磷布韦联合利巴韦林在无肝硬化患者中取得高SVR12(94%),肝硬化患者SVR12较低(79%)。
研究设计与样本
- 开放标签多中心试验,在加拿大15个中心纳入111例初治基因3型HCV感染患者,含代偿期肝硬化者,均接受来迪派韦-索磷布韦(90 mg和400 mg)联合基于体重的利巴韦林治疗12周。
主要发现
- 111例中105例(95%)为3a亚型,39例(35%)有代偿期肝硬化。
- 总体SVR12为99/111(89%;95%CI 82%-94%)。
- 肝硬化患者SVR12为31/39(79%),无肝硬化患者为68/72(94%)。
- 治疗失败者未出现治疗 emergent 耐药突变。
- 最常见不良事件为乏力(51%)、头痛(36%)和恶心(23%)。
关键数值与推荐
- 主要终点为治疗结束后12周持续病毒学应答(SVR12)。
- 1例患者因肝癌终止治疗,停药后22天死亡。
临床怎么用
- 对于初治基因3型HCV无肝硬化患者,12周来迪派韦-索磷布韦联合利巴韦林可作为取得高SVR12的治疗选择。
- 代偿期肝硬化患者接受该方案SVR12较低,临床决策需权衡。
- 治疗失败者未出现治疗 emergent 耐药突变,可能为后续治疗选择提供参考。
局限性
- 开放标签设计,无对照arm。
- 样本量有限(111例),肝硬化亚组仅39例。
- 仅纳入加拿大15个中心患者,外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients chronically infected with genotype 3 hepatitis C virus (HCV) have faster disease progression and are less responsive to current direct-acting antiviral regimens than patients infected with other genotypes. We conducted an open-label trial to evaluate the safety, tolerability, and efficacy of ledipasvir and sofosbuvir plus ribavirin in patients with genotype 3 HCV infection. METHODS: We enrolled treatment-naive patients with and without compensated cirrhosis at 15 sites in Canada. All patients were treated with ledipasvir-sofosbuvir (90 mg and 400 mg) plus weight-based ribavirin for 12 weeks. The primary endpoint was sustained virologic response 12 weeks after treatment (SVR12). Secondary endpoints included evaluation of baseline and treatment-emergent drug resistance. RESULTS: Of the 111 patients enrolled, 105 (95%) had subtype 3a HCV and 39 (35%) had compensated cirrhosis. SVR12 was achieved by 99 of 111 patients (89%; 95% confidence interval, 82%-94%). Of the 39 patients with cirrhosis, 31 (79%) achieved SVR12, compared with 68 of 72 (94%) patients without cirrhosis. No treatment-emergent resistance mutations occurred in those who failed treatment. One patient discontinued treatment due to liver cancer and died 22 days after treatment discontinuation. The most common adverse events were fatigue (51%), headache (36%), and nausea (23%). CONCLUSIONS: In this multicenter trial involving treatment-naive patients with genotype 3 HCV, 12 weeks of ledipasvir-sofosbuvir provided a high level of SVR in those without cirrhosis. CLINICAL TRIALS REGISTRATION: NCT02413593.
引用
- Feld JJ, Ramji A, Shafran SD, et al. Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study. Clin Infect Dis. 2017. PMID: 28535298. doi:10.1093/cid/cix289
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。